Table 1.

Longterm efficacy of 3 years of continuous etanercept treatment in patients with early axial spondyloarthritis (axSpA). Data at baseline after 1, 2, and 3 years of treatment with etanercept. Data shown based on study population (n = 61). Data shown for the study population based on the last observation carried forward method as mean values (SD) unless otherwise stated.

VariablesAS, n = 31nr-axSpA, n = 30p*p**
BLYear 1Year 2Year 3BLYear 1Year 2Year 3
BASDAI, 0–10, mean (SD)5.6 (1.3)2.8 (2.1)2.6 (2.5)2.7 (2.5)5.7 (1.2)2.6 (2.3)2.7 (2.4)2.4 (2.3)0.870.89
BASFI, 0–10, mean (SD)4.5 (2.1)2.3 (2.1)2.3 (2.4)2.3 (2.3)4.3 (2.0)1.8 (1.9)1.8 (1.9)1.7 (1.9)0.710.98
ASDAS, 0–∞, mean (SD)3.3 (0.7)1.7 (0.8)1.6 (1)1.6 (1)3.4 (0.8)1.7 (1.1)1.6 (1.2)1.5 (1)0.140.65
BASMI, 0–10, mean (SD)1.8 (1.7)2 (1.9)2 (1.8)2.1 (1.7)1.6 (1.5)1.3 (1.5)1.2 (1.5)1.1 (1.5)0.710.77
Joint count, 0–64, mean (SD)1.1 (1.6)0 (0)0.1 (0.4)0.1 (0.4)2.4 (4.5)0.2 (0.6)0.2 (0.9)0.1 (0.6)0.560.85
Enthesitis score, 0–17, mean (SD)4.1 (4.3)1.9 (3.8)1.5 (3.5)1.5 (3.5)3.7 (3.5)1.4 (3.7)1.5 (3.6)1.7 (3.8)0.640.44
CRP, mean mg/l (SD)11 (13.4)3.8 (4.5)3.9 (5.6)3 (4.1)9.9 (13.8)5.3 (11.3)4.6 (10.9)5 (11.8)0.670.90
MRI spine score, 0–69, mean (SD)***2.3 (4.3)NA0.6 (0.8)0.9 (1.2)1.3 (2.5)NA0.8 (1.7)1 (2.2)0.110.28
MRI SI joint score, 0–24, mean (SD)***8.5 (7.4)NA3 (2.7)2.5 (2.9)6.2 (5.5)NA1.4 (1.5)2 (2.3)0.640.29
ASAS partial remission (%)NA29%39%26%NA40%40%33%NANA
ASDAS inactive disease (%)NA32%35%32%NA40%40%50%NANA
ASDAS major improvement (%)NA29%32%26%NA40%33%37%NANA
  • * Mixed model to assess whether there is change in time between years 1, 2, and 3.

  • ** Mixed model to assess whether the 2 groups differ in their change in time between years 1, 2, and 3.

  • *** MRI data shown for completers of whom complete sets of MRI were available at baseline, Year 2, and Year 3 of continuous etanercept treatment; these were n = 17 patients with AS and n = 24 patients with nr-axSpA. BL: baseline; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASMI: Bath Ankylosing Spondylitis Mobility Index; CRP: C-reactive protein; MRI: magnetic resonance imaging; SI joint: sacroiliac joint; ASAS: Assessment of SpondyloArthritis international Society; NA: not applicable; nr-axSpA: nonradiographic SpA.